Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can fewer eye injections dry the retina in wet AMD?

NCT ID NCT02246829

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying aflibercept (Eylea), an anti-VEGF drug given as an injection into the eye, in adults aged 50 and older with wet age-related macular degeneration. Everyone in the trial receives three monthly loading doses over 12 weeks. The team uses detailed retinal scans to track when fluid clears from the retina and how the eye's structure and vision change. The goal is to see whether the standard three monthly injections are all needed, or whether some patients respond quickly enough that fewer doses could work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aflibercept, an anti-VEGF drug given as an eye injection
What this could lead to
If it works, doctors may learn whether fewer monthly eye injections are enough to dry the retina in wet AMD, which could mean fewer clinic visits and less treatment burden.
What could go wrong
The trial is small, with about 50 participants, and follows people for only 12 weeks. Results may not apply to everyone with wet AMD, and eye injections carry risks such as infection, bleeding, or retinal detachment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

50 people

The number who actually took part.

Start date

Sep 2014

Finished

Jun 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women ≥ 50 years of age * Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affects the fovea as evidenced by FA in the study eye * Signed Informed Consent * Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures. Exclusion Criteria: * Prior treatment with anti-VEGF therapy in the study eye * Active or suspected ocular or periocular infection. * Active severe intraocular inflammation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular age-related macular degeneration of all subtypes

Contacts and locations

Locations

  • Cabinet d'ophtalmologie 1 rue Pougin de la Maisonneuve

    Montargis, 45200, France

  • Centre Ophtalmologie Transparence 30 Boulevard Heurteloup

    Tours, 37000, France

  • Centre ophtalmique d'imagerie et de laser (CIL) 11 rue Antoine Bourdelle

    Paris, 75011, France

  • Sce Ophtalmologie CHU Nantes 1 place Alexis Ricordeau

    Nantes, 44093, France

  • Sce Ophtalmologie Hôpital Lariboisière 2 rue Ambroise Paré

    Paris, 75475, France

  • Sce du Pr SAHEL Fondation ROTHSCHILD 25 rue Manin

    Paris, 75019, France

  • Service Ophtalmologie CHU DIJON 14 rue Gaffarel BP 77908

    Dijon, 21079, France

  • Service Opthalmo 2 Clinique Mathilde 4 rue de Lessard

    Rouen, 76100, France

  • Service d'Ophtalmologie Hôpital de la croix rousse

    Lyon, 69317, France

  • Service d'ophtalmologie Hôpital Henri Mondor 40, avenue de Verdun

    Créteil, 94000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.